Company* (Symbol)




Status (Date)**


Aastrom Biosciences Inc. (ASTM)

Aastrom Replicell Cell Production System

Automated clinical system designed to produce patient-specific cells for treatment of various diseases

Stem-cell therapy for patients with breast cancer

Results from Phase II trial published in 3/15/00 issue of Blood (3/15)

AltaRex Corp. (Canada; TSE:AXO)

BrevaRex MAb

Murine monoclonal antibody against the MUC1 cancer antigen

MUC1-positive cancer

Reported preliminary Phase I results (3/20)

AltaRex Corp. (Canada; TSE:AXO)

OvaRex MAb

Modified murine monoclonal antibody that binds to CA125 cancer antigen

Ovarian cancer

Company reported results for first patient tested for immune response in open-label Phase II trial (3/7)

Amgen Inc. (AMGN)


Sustained duration form granulocyte-colony stimulating factor; consists of the G-CSF protein binded to polyethylene glycol

Chemotherapy-induced neutropenia in breast cancer patients

Drug Royalty Corp. Inc. (TSE:DRI) described Amgen's Phase II results (3/21)

Antigenics Inc. (AGEN)


Cancer vaccine consisting of purified, patient-specific heat shock protein-peptide complexes

Non-Hodgkin's lymphoma

Initiated Phase II trial (3/20)

Aronex Pharmaceuticals Inc. (ARNX)


Liposomal anthracycline

Refractory breast cancer

Initiated Phase II trial (3/28)

Avax Technologies Inc. (AVXT)


Therapeutic vaccine; tumor cells removed from patient, modified with hapten (DNP; dinitrophenyl), then injected back into patient (along with cyclophosphamide)

Metastatic melanoma (Stage III)

Reported interim results from low-dose Phase II trial (3/15)

Avax Technologies Inc. (AVXT)


Therapeutic vaccine; tumor cells removed from patient, modified with hapten (DNP; dinitrophenyl), then injected back into patient (along with cyclophosphamide)

Metastatic melanoma (Stage IV)

Initiated Phase II trial (3/28)

Biomira Inc. (Canada; BIOM)


Vaccine incorporates a synthetic 25-amino-acid sequence of the MUC1 cancer mucin encapsulated in a synthetic liposomal delivery system

Non-small-cell lung cancer

Presented immune-response data gathered in Phase II trial at the Biotechnology Industry Organization meeting in Boston (3/27)

Cell Pathways Inc. (CLPA)


Exisulind; orally active drug designed to induce apoptosis in precancerous cells; inhibits a cyclic GMP phospho-diesterase

Children with familial adenomatous polyposis

Completed enrollment in open-label Phase II trial (3/29)

Eligix Inc.*

HDM (High Density Microparticle) technology

Use of high-density micro-particles coated with a monoclonal antibody specific to CD8+ cells to selectively deplete CD8+ lymphocytes from donor lymphocyte infusions after relapse of hematologic malignancies

Protection from from graft-vs.-host disease in patients receiving donor lymphocyte infusions to achieve remission

Reported results of Phase I/II trial at the European Bone Marrow Transplant Meeting in Innsbruck, Austria (3/16)

EntreMed Inc. (ENMD)


2-mehtoxyestradiol; small-molecule, orally active angiogenesis inhibitor

Advanced breast cancer

Initiated Phase I trial (3/31)

FeRx Inc.*


Sustained-release formulation of doxorubicin delivered via magnetic targeted carriers (micro-particles, composed of elemental iron and activated carbon)

Primary liver cancer

Reported data from Phase I/II trial (3/27)

Genta Inc. (GNTA)


Antisense compound; synthetic DNA strands that bind to mRNA for the bcl2 gene (proto-oncogene)

Advanced malignant melanoma

Initiated pivotal study of G3139 in combination with dacarbazine (3/9)

IBC Pharmaceuticals LLC (joint venture between Immunomedics Inc. [IMMU] and Beckman Coulter Corp. [NYSE:BEC])


Bispecific antibody delivered via injection; one arm (injected first) binds to CEA+ tumors; radiation carrier arm is subsequently injected

Solid tumors

Initiated Phase I/II trial (3/1)

Ilex Oncology Inc. (ILXO)


Vitamin D3 analogue

Refractory solid tumors

Initiated a second Phase I trial using the drug alone and in combination with dexamethasone (3/21)

The Immune Response Corp. (IMNR)


Cancer vaccine utilizing a fibroblast cell line (genetically modified to secrete granulocyte macrophage colony-stimulating factor) mixed with irradiated tumor (glioma) cell lines to seek to boost antitumor immune response

Prevention of brain tumor recurrence

Initiated Phase I trial (3/8)

Immunomedics Inc. (IMMU)


Use of ex vivo genetic engineering of T lymphocytes involving insertion of gene controlling the binding region of humanized antibody against carcinoembryonic antigen

Colorectal cancer

Initiated Phase I trial (3/2)

Introgen Therapeutics Inc.* and Aventis Pharmaceuticals (unit of Aventis SA [NYSE:AVE])


Intratumoral delivery of p53 gene via adenoviral vector

Head and neck cancer

The Recombinant DNA Advisory Committee of the National Institutes of Health cleared Phase III protocol (3/10)

Ligand Pharmaceuticals Inc. (LGND)

Targretin capsules (FDA-approved)

Bexarotene; synthetic retinoid analogue that selectively activates retinoid X receptors; oral

Refractory cutaneous T-cell lymphoma

Presented data from two Phase II/III trials in posters at the American Academy of Dermatology's 58th Annual Meeting in San Francisco (3/13)

Matrix Pharmaceutical Inc. (MATX)


Nucleoside analogue believed to inhibit DNA synthesis directly by incorporation into DNA strands and indirectly by blocking the action ribonucleotide reductase, an enzyme important to nucleotide formation; structure and action similar to gemcitabine


Initiated two combination therapy trials, one with cisplatin and one with 5-fluorouracil (3/22)

NeoPharm Inc. (AMEX:NEO) and Pharmacia & Upjohn (NYSE:PNU)


Liposomal-encapsulated formulation of paclitaxel


Completed Phase I studies (3/15)

NeoRx Corp. (NERX)

Skeletal Targeted Radiotherapy

Small-molecule carrier of the radionuclide holmium-166, designed to deliver radiation therapy selectively to bone, and especially those areas of bone undergoing increased metabolism

Ewing's sarcoma

Initiated clinical trial (3/24)

Procept Inc. (subsidiary of Inc.; HVDC)


06-Benzylguanine (BG); chemosensitzing agent designed to overcome tumor resistance to 06-alkylating agents; BG inactivates AGT, a DNA repair protein

Advanced soft tissue sarcoma

Initiated Phase II trial sponsored by the National Cancer Institute (3/22)

Sepracor Inc. (SEPR)


(S) ­ doxazosin; single-isomer form of Pfizer Inc.'s (NYSE:PFE) Cardura

Benign prostatic hyperplasia

Initiated Phase I trial (3/13)

SuperGen Inc. (SUPG)


Decitabine; inhibits DNA methyltransferase activity

Non-small-cell lung cancer

Presented data from Phase I trial at the 10th International Congress on Anticancer Treatment (3/2)

SuperGen Inc. (SUPG)


Decitabine; inhibits DNA methyltransferase activity

Myelodysplastic syndrome

Results from Phase II study were published in the 3/00 issue of the Journal of Clinical Oncology (3/15)

Techniclone Inc. (TCLN)


LYM-1 murine monoclonal antibody to HLA-DR10 protein (cell surface marker present on 80% of lymphoma cells), labeled with I-131

Non-Hodgkin's B cell lymphoma

Techniclone clarified Oncolym's clinical status in response to media reports; partner Schering AG (Germany) is shifting to a higher, single-dose regimen for future trials in place of the previous three-dose regimen; new Phase I/II slated for second quarter (3/20)

Vion Pharmaceuticals Inc. (VION)


Tumor amplified protein expression therapy; Salmonella vector consisting of highly attenuated bacteria that preferentially replicate in tumors

Advanced, refractory cancers

Received approval to begin Phase I trial at the National Cancer Institute (3/28)

Vion Pharmaceuticals Inc. (VION)


Ribonucleotide reductase inhibitor that blocks a crucial step in the synthesis of DNA


Completed Phase I trial (3/2)

Xenova Group plc (UK; XNVA)


P-glycoprotein pump that restores the sensitivity of multidrug-resistant cancer cells to specific cytotoxic drugs

Ovarian cancer

Reported results of Phase IIa trial of XR9576 and paclitaxel; announced Phase III trials would begin later this year (3/7)


Avant Immunotherapeutics Inc. (AVAN)


Soluble form of complement receptor 1 (CR1), designed to inhibit complement proteins

Infants undergoing cardiac surgery

Reported results of Phase I/II trial (3/27)

AVI BioPharma Inc. AVII)


Synthetic polymer antisense compound targeting c-myc oncogene, which has been implicated in cell proliferation

Prevention of restenosis

Completed Phase I trial and initiated Phase II trial (3/16)

Avigen Inc. (AVGN)


Factor IX gene therapy delivered via adeno-associated viral vector; injected into the thigh

Hemophilia B

Data from Phase I trial at Stanford University and Children's Hospital of Philadelphia was published in 3/00 issue of Nature Genetics (3/1)

Chiron Corp. (CHIR)


Recombinant fibroblast growth factor-2 (FGF-2)

Symptomatic coronary artery disease patients who are not candidates for angioplasty or bypass surgery

Phase II trial failed to achieve primary endpoint of statistically significant improvement in exercise testing at 90 days; positive trends were observed in angina reduction in the trial, dubbed FIRST (FGF-2 Initiating Revascularization Support Trial) (3/12)

Collateral Therapeutics Inc. (CLTX), Schering AG (Germany), and Berlex Laboratories (subisidiary of Schering)

Generx (Ad5FGF4)

Angiogenic gene therapy; the fibroblast growth factor-4 gene (FGF-4) is delivered to the heart via an adenoviral vector during a diagnostic angiogram

Stable exertional angina due to coronary artery disease

Reported preliminary results from Phase I/II trial, dubbed AGENT (Angiogenic GENe Therapy) (3/20)

Connetics Corp. (CNCT)


Recombinant form of human relaxin H2

Peripheral vascular disease

Announced plan to expand clinical testing program into new indication with request for regulatory approval of Phase II trial (3/9)

COR Therapeutics Inc. (CORR) and Schering-Plough Corp. (NYSE: SGP)

Integrilin (FDA-approved)

Eptifibatide; small-molecule compound (derived from rattlesnake venom) that inhibits GPIIb/IIIa receptor, which mediates platelet aggregation

Non-urgent balloon angioplasty combined with intracoronary stenting

Reported final results for the primary endpoint of ESPRIT (Enhanced Suppression of Platelet Receptor GPIIb-IIIa Using Integrilin Therapy) trial at the American College of Cardiology's (ACC) 49th Annual Meeting (3/14)

CV Therapeutics Inc. (CVTX)


Selective adenosine A1 receptor antagonist

Atrial arrhythmias

Presented Phase I trial results at the ACC meeting (3/14)

CV Therapeutics Inc. (CVTX)


Selective adenosine A1 receptor antagonist

Atrial fibrillation

Initiated second Phase II trial (3/22)

CV Therapeutics Inc. (CVTX)


Piperazine acetamide

Chronic angina

Presented positive Phase III trial data at the ACC meeting (3/15)

CytRx Corp. (CYTR)


Purified poloxamer 188; surfactant molecule that alters the way cells and molecules interact with water

Sickle cell disease

Company conducted additional analysis of data from Phase III trial, in which Flocor failed to meet primary efficacy endpoint of decreasing length of sickle cell anemia-associated vascular occlusive crisis (12/99); CytRx intends to proceed with development and conduct an additional trial (3/14)

Elanex Pharma Group*


Recombinant erythropoietin; Elanex said product differs from Amgen's (AMGN) by using shorter APA1 DNA fragment and BHK host hells; company claims its version of EPO can be administered in lower doses


Released dosing information from clinical trial (3/20)

Immunex Corp. (IMNX)

Enbrel (FDA-approved)

Recombinant, soluble T75 tumor necrosis factor receptor (TNFr) linked to the Fc portion of human IgG1

Advanced heart failure

Reported trial data at the ACC meeting (3/15)

Genentech Inc. (NYSE: DNA)


Tenecteplase; second-generation recombinant plasminogen activator with greater specificity to fibrin than Genentech's first-generation tissue-plasminogen activator (Activase)

Acute myocardial infarction

Announced plan for four clinical trials of TNKase in combination with various antithrombotic agents; trials will enroll a total of 9,000 patients; the ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens) is the largest of the trials and will enroll 6,000 patients in three treatment arms: tenecteplase and heparin sodium; tenecteplase and enoxaparin sodium (low-molecular-weight heparin); and a half dose of tenecteplase combined with a low dose of heparin sodium and abciximab (ReoPro, developed by Johnson & Johnson subsidiary Centocor Inc.; NYSE:JNJ) (3/13)

Texas Biotechnology Corp. (AMEX:TXB) and SmithKline Beecham plc (UK;NYSE:SBH)

Novastan Injection

Synthetic small molecule (argotroban) derived from arginine; acts as a direct inhibitor of thrombin

Anticoagulant therapy for patients with heparin-induced thrombocytopenia

Presented positive Phase III trial results at the ACC meeting (3/13)

United Therapeutics Corp. (UTHR)


Structural analogue of prostacylcin

Pulmonary hypertension

Reported positive preliminary results from pivotal trial (3/27)


Axonyx Inc. (OTC BB:AXYX)


Brain-targeted, reversible inhibitor of acetylcho-linesterase enzyme

Alzheimer's disease

Reported results from Phase I trial (3/28)

Boston Life Sciences Inc. (BLSI)


Radioimaging probe for dopamine neurons

Diagnosis of early Parkinson's disease

Completed enrollment in Phase III trial (3/15)

NeoTherapeutics Inc. (NEOT)

Neotrofin (AIT-082)

Small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neurotrophic factors

Alzheimer's disease

Initiated Phase II/III trial (3/29)

Neurocrine Biosciences Inc. (NBIX)


Type 1 GABA-a receptor agonist; chemically distinct from benzodiazepines


Initiated first of 14 trials slated for 2000 (3/8)

Pharmos Corp. (PARS)


Non-psychotropic synthetic analogue of marijuana (intravenous)

Traumatic brain injury

Completed third cohort of Phase II trial (3/7)

Repligen Corp. (RGEN)


Secretin hormone

Autism in children

Initiated Phase II trial (3/29)


Amerimmune Pharmaceuticals Inc. (OTC BB: AMUN)


Monoclonal antibody that blocks certain adhesion molecules on killer T cells

HIV infection

Initiated Phase I/II trial (3/6)

Cangene Corp. (Canada; TSE:CNJ)


Anti-hepatitis B hyperimmune product

Hepatitis B infection

Initiated pivotal trial (3/17)

Cubist Pharmaceuticals Inc. (CBST)


Lipopeptide antibiotic (intravenous)

Serious and life-threatening grampositive bacterial infections

Presented data from two Phase II trials at the Centers for Disease Control's 4th Decennial Conference on Nosocomial and Healthcare-Associated Infections in Atlanta (3/6)

Enzo Biochem Inc. (NYSE:ENZ)


Immune modulation treatment that involves oral administration of specific hepatitis B proteins to control the antiviral immune response

Chronic hepatitis B virus infections

Announced preliminary results of Phase I trial (3/28)

ImmuCell Corp. (ICCC)


Bovine anti-Clostridium difficile immunoglobulins; produced from the milk of hyperimmunized cows

Clostridium difficile-associated diarrhea

Reported preliminary results of open-label Phase I/II trial (3/28)

The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co. [NYSE:WLA])


Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant)

HIV-1 infection

Presented data from open-label trial measuring immune response to Remune and highly active antiretroviral therapy (HAART) (3/6)

Inhibitex Inc.*

S. aureus Immune Globulin Intravenous (SA-IGIV; human)

Antibody-based product targeting antibiotic-resistant Staphylococcus aureus; highly purified human immunoglobulin product derived from pooled adult human plasma selected for levels of antibodies specific for S. aureus

Prevention of S. aureus infection in patients receiving hemodialysis

Initiated Phase I/II trial (3/22)

Isis Pharmaceuticals Inc. (ISIP) and Elan Corp. plc (NYSE:ELN)

ISIS 14803

Antisense drug; 20-base phosphorothioate oligonucleotide designed to inhibit replication of hepatitis C virus

Chronic hepatitis C

Initiated Phase I/II trial (3/1)

Palatin Technologies Inc (AMEX:PTN)


Radiolabeled monoclonal-antibody-based system for imaging infection (product binds specifically to white blood cells)

Diagnosis of equivocal appendicitis

Clinical trial results published in 3/00 issue of The Journal of Nuclear Medicine (3/23)

Trimeris Inc. (TRMS) and Hoffmann-La Roche Inc. (Switzerland)


Antiviral fusion-inhibiting compound (twice-daily subcutaneous injection)

HIV infection

Initiated Phase II open-label trial to evaluate alternative formulations (3/14)


Alliance Pharmaceutical Corp. (ALLP)


Perflubron; oxygen-carrying liquid that is used in partial liquid ventilation method

Acute lung injury and acute respiratory distress syndrome

Data Safety and Monitoring Board reviewed safety data in Phase II/III trial and recommended continuation; as a result of a separate interim analysis, the company expanded the study to include 15 additional patients for each of the three study arms (3/16)

Amarillo Biosciences Inc. (OTC BB: AMAR)


Orally administered interferon-alpha

Fibromyalgia syndrome

Reported data from Phase II trial (3/9)

Anika Therapeutics Inc. (ANIK) and Zimmer Inc. (subsidiary of Bristol-Myers Squibb Co. [NYSE:BMY])


Ultra-pure, high-molecular-weight naturally derived hyaluronic acid (intra-articular injection)

Osteoarthritis of the knee

Completed Phase III trial (3/15)

Ares-Serono Group (Switzerland)

Rebif beta-1a

Recombinant interferon

Relapsing-remitting multiple sclerosis

Reported four-year data from PRISMS (Prevention of Relapses and Disability By Interferon Beta-1a Subcutaneously in Multiple Sclerosis) trial (3/23)

Carrington Laboratories Inc. (CARN)

Aliminase (formerly CARN 1000)

Oral anti-inflammatory complex carbohydrate

Ulcerative colitis

Discontinued development based on Phase III failure to achieve statistically significant improvement (3/24)

Cellegy Pharmaceuticals Inc. (CLGY)


Proprietary formulation of nitroglycerin ointment

Reduction of pain associated with anal fissures

Initiated second Phase III trial (3/9)

Cellegy Pharmaceuticals Inc. (CLGY)


Transdermal testosterone gel

Male hypogonadism

Initiated pivotal Phase III trial (3/29)

Connetics Corp. (CNCT)

Olux Foam

Foam formulation of clobetasol proprionate 0.05%; super-high-potency corticosteroid

Scalp psoriasis

Presented positive Phase III trial data at the 58th Annual Meeting of the American Academy of Dermatology in San Francisco (3/11)

Discovery Therapeutics Inc. (DSCO)

SuperVent Aerosol Solution

Tyloxapol (non-anionic alkalaryl and polyether alcohol); anti-inflammatory inhibitor of NF-(kappa)B

Cystic fibrosis

Reported preliminary data from Phase IIa trial (3/28)

Dynavax Technologies Corp.*


Conjugate of purified ragweed allergen (Amb a 1) to an immunostimulatory polynucleotide DNA sequence

Ragweed allergy

Presented results of Phase I open-label trial at the 56th Annual American Academy of Allergy, Asthma and Immunology meeting in San Diego (3/8)

Genentech Inc. (NYSE:DNA), Novartis AG (Switzerland) and Tanox Inc. (TNOX)


Olizumab/rhuMAb-E25; recombinant humanized monoclonal antibody to IgE; subcutaneous


Reported positive data from two Phase III trials at the 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Diego (3/4)

Genzyme Tissue Repair (GZTR)

Carticel (FDA-approved)

Autologous cultured chondrocytes

Repair of damaged cartilage on the thigh-bone part of the knee

Reported summary of the sixth report of the company's Cartilage Repair Registry at the annual meeting of the American Academy of Orthopedic Surgeons in Orlando (3/17)

Gliatech Inc. (GLIA)

Adcon-L (FDA-approved)

Anti-adhesion barrier gel (semisynthetic carbohydrate polymer)

To inhibit post-operative adhesions involving spinal cord and nerve roots, and to improve patient outcome following lumbar disc surgery

Company provided information addressing concerns about alleged increase in cerebrospinal fluid leaks associated with the product (3/20)

Idec Pharmaceuticals Corp. (IDPH) and Mitsubishi Chemical Corp. (Japan)


Primatized anti-B7-1 monoclonal antibody; blocks binding of B7-1 ligand on antigen-presenting cells to CD28 receptor on T cells

Moderate to severe psoriasis

Reported results from Phase I trial (3/15)

Immunex Corp. (IMNX)

Enbrel (FDA-approved)

Etanercept; recombinant, soluble p75 tumor necrosis factor receptor (TNFr)linked to the Fc portion of human IgG1

Juvenile rheumatoid arthritis

Positive trial data published in 3/16/00 issue of The New England Journal of Medicine (3/15)

InKine Pharmaceutical Co. Inc. (INKP)


Oral steroid, designed as safer alternative to prednisone

Idiopathic thrombocytopenic purpura

Initiated single-dose human pharmacokinetic study (3/6)

Nortran Pharmaceuticals Inc. (Canada; CDNX:NRT)


Non-narcotic cough suppressant

Chronic idiopathic

Initiated Phase II trial (3/28)

Pharmadigm Inc.*


Synthetic injectable dosage form of dehydroepiandosterone (DHEA) sulfate

Severely burned patients undergoing autologous skin grafting

Presented Phase II results at 32nd Annual Meeting of the American Burn Association in Las Vegas (3/17)

Pharming Group NV (the Netherlands) and Genzyme General (GENZ)


Transgenic recombinant human alpha-glucosidase

Infants with Pompe's disease

Reported Phase II results (3/15)

QLT PhotoTherapeutics Inc. (QLTI) and CIBA Vision (eye care unit of Novartis AG; Switzerland)


Verteporfin for injection; photodynamic therapy is activated through use of specially designed laser that produces low-level, non-thermal 689-nm light

Age-related macular degeneration

Expanded treatment IND trial in North America to add 200 new sites (3/15); reported positive two-year results from Phase III study and one-year results from separate Phase IIIb study (3/28)

Regeneron Pharmaceuticals Inc. (REGN) and The Procter & Gamble Co. (NYSE:PG)


Second-generation ciliary neurotrophic factor


Initiated Phase II trial that will not exclude patients with prior history of herpes cold sores; in Phase I trial, some patients who received higher doses who had previously contracted herpes simplex virus experienced cold sores related to HSV reactivation (3/28)

Xoma Ltd. (XOMA)


Recombinant humanized antibody against CD11a

Prevention of rejection of kidney transplants

Initiated Phase I/II trial of product in combination with standard immunosuppressive drugs (3/30)


* Indicates a privately held company

** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SBI=Stockholm Borsinformation; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed

ACC = American College of Cardiology